Results 241 to 250 of about 56,406 (298)

Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine the test performance of cutaneous phosphorylated alpha‐synuclein (P‐SYN) in dementia with Lewy bodies (DLB), individuals with reduced Montreal Cognitive Assessment (MoCA) and healthy controls. Methods This is the first subgroup analysis of the Synuclein‐One study, a prospective, blinded study evaluating P‐SYN detection ...
Christopher H. Gibbons, Todd Levine, Charles H. Adler, Bailey Bellaire, Ningshan Wang, Pinky Agarwal, Georgina M. Aldridge, Alexandru Barboi, Daniel Claassen, Virgilio G. H. Evidente, Douglas Galasko, Alejandra Gonzalez‐Duarte, Ramon Gil, Mark Gudesblatt, Stuart H. Isaacson, Horacio Kaufmann, Pravin Khemani, Rajeev Kumar, Guillaume Lamotte, Andy J. Liu, Nikolaus R. McFarland, Mitchell G. Miglis, Adam Reynolds, Gregory A. Sahagian, Marie‐Helene Saint‐Hilaire, Julie B. Schwartzbard, Wolfgang Singer, Michael J. Soileau, Steven Vernino, Patricio Millar Vernetti, Oleg Yerstein, Roy Freeman   +31 more
wiley   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Editorial: Molecular studies and therapeutic approaches on BRCA-associated cancers. [PDF]

Front Mol Biosci
Bhat A, Wang X, Stephen P.
europepmc   +1 more source

Touching (Proximity) as a Companion Diagnostic Test

Journal of Thoracic Oncology
Niki Gavrielatou, Parmees Fazeli, David L. Rimm   +2 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Epigenetic-Based Companion Diagnostics

Personalized Medicine, 2011
In current medical practice, when a patient is diagnosed with cancer the treating physician generally follows a standard protocol, assigning the treatment that gives a favorable response in the largest proportion of patients. However, in many individual instances this approach may not be the most effective solution and, typically, treatment is only ...
Leander, Van Neste, Gregory R, Jones, Wim, Van Criekinge, James S, Clark   +3 more
openaire   +2 more sources

Companion Diagnostics and Molecular Imaging

The Cancer Journal, 2015
Companion diagnostics (CDx) is a positive attempt in the direction of improving the drug development process, especially in the field of oncology, with the advent of newer targeted therapies. It helps the oncologist in deciding the choice of treatment for the individual patient.
Ameya D, Puranik, Harshad R, Kulkarni, Richard P, Baum   +2 more
openaire   +2 more sources

Companion diagnostics und liquid biopsy

2017
The chapter describes potential POCT applications for companion diagnostics and liquid biopsy. Companion diagnostics are in-vitro methods, which provide information about the suitability and effectiveness of a particular therapeutic drug for a patient prior to its administration. It therefore allows stratification of patient populations.
Frauke Adams, Jörg-M. Hollidt, Christof Winter   +2 more
openaire   +1 more source

Regulatory Considerations for Companion Diagnostic Devices

Biomarkers in Medicine, 2015
The emergence of companion diagnostic devices has been spurred by drug discovery and development efforts towards targeted therapies, particularly in oncology. Companion diagnostics and their corresponding therapeutics are often codeveloped, or developed in parallel, to ensure the safe and effective use of the products.
Eunice Y, Lee, Hsin-Chieh Jennifer, Shen
openaire   +2 more sources

Clinical application of companion diagnostics

Trends in Molecular Medicine, 2015
Optimally, any prescription should rely on an in-depth understanding of the disease biology and the mechanism of action of the drug. However, despite the hype about precision medicine in recent years, the prescription of most drugs is still, except for a few anticancer drugs, largely based on 'trial and error' and not on solid pharmacogenomic biomarker
openaire   +2 more sources

First Comprehensive Companion Diagnostic OK'd

Cancer Discovery, 2018
Abstract The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test.
openaire   +2 more sources